Hepatocyte growth factor and antibodies to HLA and MICA antigens in heart transplant recipients

Tissue Antigens

Volumn 76, Issue 5, 2010, Pages 380-386

  Pavlova, Y A ^a   Malek, I ^a   Honsova, E ^a   Netuka, I ^a   Sochman, J ^a   Lodererova, A ^a   Kolesar, L ^a   Striz, I ^a   Skibova, J ^a   Slavcev, A ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

Acute rejection; Heart transplantation; Hepatocyte growth factor; HLA antibodies; MICA antibodies

Indexed keywords

ANTIBODY; ANTIGEN; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; MHC CLASS 1 CHAIN RELATED ANTIGEN A; MICA ANTIBODY; SCATTER FACTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CORRELATION ANALYSIS; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL;

ACUTE DISEASE; ADULT; BIOLOGICAL MARKERS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HEPATOCYTE GROWTH FACTOR; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; ISOANTIBODIES; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES;

EID: 78649408603     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/j.1399-0039.2010.01523.x     Document Type: Article

References (30)

1. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003: 22: 58-69.
2. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005: 24: 1710-20.
3. Billingham ME, Carry NR, Hammond ME, Kemnitz J, Marboe C. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: heart rejection study group. J Heart Lung Transplant 1990: 9: 587-93.
4. Rodriguez ER, Skojec DV, Tan CD, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 2005: 5: 2778-85.
5. Crespo-Leiro MG, Veiga-Barreiro A, Domenech N, et al. Humoral heart rejection (severe allograft dysfunction with no signs of cellular rejection or ischemia): incidence, management, and the value of C4d for diagnosis. Am J Transplant 2005: 5: 2560-4.
6. Fedson SE, Daniel SS, Husain AN. Immunohistochemistry staining of C4d to diagnose antibody-mediated rejection in cardiac transplantation. J Heart Lung Transplant 2008: 27: 372-9.
7. Terasaki PI, Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005: 17: 541-5.
8. Rose ML, Smith JD. Clinical relevance of complement-fixing antibodies in cardiac transplantation. Hum Immunol 2009: 70: 605-9.
9. Kaczmarek I, Deutsch MA, Kauke T, et al. Donor-specific HLA alloantibodies: long-term impact on cardiac allograft vasculopathy and mortality after heart transplant. Exp Clin Transplant 2008: 6: 229-35.
10. Stastny P, Lavingia B, Fixler DE, Yancy CW, Ring WS. Antibodies against donor human leukocyte antigens and the outcome of cardiac allografts in adults and children. Transplantation 2007: 84: 738-45.
11. Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005: 80: 1019-25.
12. Suarez-Alvarez B, Lopez-Vazquez A, Diaz-Pena R, et al. Post-transplant soluble MICA and MICA antibodies predict subsequent heart graft outcome. Transpl Immunol 2006: 17: 43-6.
13. Suárez-Alvarez B, López-Vázquez A, Gonzalez MZ, et al.The relationship of anti-MICA antibodies and MICA expression with heart allograft rejection. Am J Transplant 2007: 7: 1842-8.
14. Kauke T, Kaczmarek I, Dick A, et al. Anti-MICA antibodies are related to adverse outcome in heart transplant recipients. J Heart Lung Transplant 2009: 28: 305-11.
15. Smith JD, Brunner VM, Jigjidsuren S, et al. Lack of effect of MICA antibodies on graft survival following heart transplantation. Am J Transplant 2009: 9: 1912-9.
16. Ichiguchi O, Yamaguchi Y, Miyanari N, et al. Enhanced hepatocyte growth factor expression associated with prolonged rat hepatic allograft survival in recipients pretreated with donor-specific blood. Transplantation 1999: 67: 115-23
17. Kitta K, Day RM, Ikeda T, Suzuki YJ. Hepatocyte growth factor protects cardiac myocytes against oxidative stress-induced apoptosis. Free Radic Biol Med 2001: 31: 902-10.
18. Nakagami H, Morishita R, Yamamoto K, et al. Anti-apoptotic action of hepatocyte growth factor through mitogen-activated protein kinase on human aortic endothelial cells. J Hypertens 2000: 18: 1411-20.
19. Yamaura K, Ito K, Tsukioka K, et al. Suppression of acute and chronic rejection by hepatocyte growth factor in a murine model of cardiac transplantation: induction of tolerance and prevention of cardiac allograft vasculopathy. Circulation 2004: 110: 1650-7.
20. Mahmoud K, Opelz G, Pelzl, et al. Evaluation of hepatocyte growth factor as a sensitive marker for early detection of acute renal allograft rejection. Transplantation 2007: 83: 1035-40.
21. Zwirska-Korczala K, Zakliczynski M, Berdowska A, Zembala M, Jochem J, Gajewska K. Diagnostic validity of hepatocyte growth factor as marker for rejection in the follow-up of patients after heart transplantation. J Heart Lung Transplant 2005: 24: 411-5.
22. Smith JD, Hamour IM, Banner NR, Rose ML. C4d Fixing, Luminex Binding Antibodies - A new Ttool for prediction of graft failure after heart transplantation. Am J Transplant 2007: 7: 2809-15.
23. He Y, Li S, Feng L, Cheng F, Ye Z, Li Y. Effect of cyclosporine on expression of MIC in human hepatocytes. Transplant Proc 2006: 38: 2231-3.
24. Quiroga I, Salio M, Koo DD, Cerundolo L, et al. Expression of MHC class I-related Chain B (MICB) molecules on renal transplant biopsies. Transplantation 2006: 81: 1196-203.
25. Suárez-Alvarez B, López-Vázquez A, Díaz-Molina B. The predictive value of soluble major histocompatibility complex class I chain-related molecule A (MICA) levels on heart allograft rejection. Transplantation 2006: 82: 354-61.
26. Zou Y, Mirbaha F, Lazaro A, Zhang Y, Lavingia B, Stastny P. MICA is a target for complement-dependent cytotoxicity with mouse monoclonal antibodies and human alloantibodies. Hum Immunol 2002: 63: 30-9.
27. Matsumoto K, Tajima H, Okazaki H, Nakamura T. Negative regulation of hepatocyte growth factor gene expression in human lung fibroblasts and leukemic cells by transforming growth factor-beta 1 and glucocorticoids. J Biol Chem 1992: 267: 24917-20.
28. Marchand-Adam S, Marchal J, Cohen M, et al. Defect of hepatocyte growth factor secretion by fibroblasts in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003: 168: 1156-61.
29. Jin YP, Jindra PT, Gong KW, Lepin EJ, Reed EF. Anti-HLA class I antibodies activate endothelial cells and promote chronic rejection. Transplantation 2005: 79: 19-21.
30. Jindra PT, Jin YP, Rozengurt E, Reed EF. HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 2008: 180: 2357-66.